Strategies for Structural Modification of Small Molecules to Improve Blood–Brain Barrier Penetration: A Recent Perspective
Top Cited Papers
- 10 September 2021
- journal article
- research article
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 64 (18) , 13152-13173
Abstract
In the development of central nervous system (CNS) drugs, the blood–brain barrier (BBB) restricts many drugs from entering the brain to exert therapeutic effects. Although many novel delivery methods of large molecule drugs have been designed to assist transport, small molecule drugs account for the vast majority of the CNS drugs used clinically. From this perspective, we review studies from the past five years that have sought to modify small molecules to increase brain exposure. Medicinal chemists make it easier for small molecules to cross the BBB by improving diffusion, reducing efflux, and activating carrier transporters. On the basis of their excellent work, we summarize strategies for structural modification of small molecules to improve BBB penetration. These strategies are expected to provide a reference for the future development of small molecule CNS drugs.Keywords
Funding Information
- China Pharmaceutical University (CPU2018GF11, CPU2018GY34)
- Natural Science Foundation of Jiangsu Province (BK20191411)
- National Natural Science Foundation of China (81573281, 81872728, 81973207)
This publication has 135 references indexed in Scilit:
- Confounding Parameters in Preclinical Assessment of Blood–Brain Barrier Permeation: An Overview With Emphasis on Species Differences and Effect of Disease StatesMolecular Pharmaceutics, 2013
- Synthesis, Biological Evaluation, and Structure–Activity Relationships of a Novel Class of Apurinic/Apyrimidinic Endonuclease 1 InhibitorsJournal of Medicinal Chemistry, 2012
- Discovery of a Novel Class of Orally Active Trypanocidal N-Myristoyltransferase InhibitorsJournal of Medicinal Chemistry, 2011
- Knowledge-Based, Central Nervous System (CNS) Lead Selection and Lead Optimization for CNS Drug DiscoveryACS Chemical Neuroscience, 2011
- GEBR-7b, a novel PDE4D selective inhibitor that improves memory in rodents at non-emetic dosesBritish Journal of Pharmacology, 2011
- Moving beyond Rules: The Development of a Central Nervous System Multiparameter Optimization (CNS MPO) Approach To Enable Alignment of Druglike PropertiesACS Chemical Neuroscience, 2010
- Defining optimum lipophilicity and molecular weight ranges for drug candidates—Molecular weight dependent lower logD limits based on permeabilityBioorganic & Medicinal Chemistry Letters, 2009
- Strategies to assess blood–brain barrier penetrationExpert Opinion on Drug Discovery, 2008
- Structure−Brain Exposure RelationshipsJournal of Medicinal Chemistry, 2006
- Characterization of the neurotoxic potential of m-methoxy-MPTP and the use of its N-ethyl analog as a means of avoiding exposure to a possible Parkinson-causing agentJournal of Medicinal Chemistry, 1986